【摘要】 目的研究糖脉康颗粒对新诊断2型糖尿病患者的肠促胰岛素(GLP-1)与胰岛素抵抗的影响。方法选取医院收治的患者31例,均进行饮食、运动治疗,并给予糖脉康颗粒(口服,每次5 g,每日3次),每2周为1个疗程,治疗2个疗程。观察并记录患者治疗前后混合餐耐量试验(MMTT)情况,对各类症状进行分析评分;收集患者MMTT中0,15,30,60,90,120 min血标本,检验并记录血糖、GLP-1、胰岛素和C-肽变化情况;记录患者治疗前后血脂、血液流变学各项指标变化及不良反应发生情况。结果治疗后,患者临床症状评分明显降低(P<0.05或P<0.01);GLP-1在60 min时增加(P<0.05),其他时间段则无差异(P>0.05),胰岛素、C-肽无明显变化(P>0.05);血糖在30,60,90,120 min明显降低(P<0.05),且未出现低血糖,无其他不良反应。结论糖脉康颗粒可有效改善新诊断2型糖尿病患者的临床症状,改善胰岛素抵抗,提高胰岛素效率,对GLP-1无明显促进作用,安全性高,值得临床推广。更多还原

【Abstract】 Objective To study the influence of Tangmaikang granule on GLP- 1 and insulin resistance in newly diagnosed type 2 diabetic patients. Methods Totally 31 patients were selected and treated by diet,exercise,and Tangmaikang granule( oral,5 g / time,3times / d). The course of treatment was two weeks,and the treatment lasted for two courses. To observe and record the MMTT of the patients before and after the treatment,analyze and evaluate the symptoms scores. The blood samples at 0,15,30,60,90,120 min during MMTT were collected,and the changes of blood glucose,insulin and C- peptide were examined and recorded. The changes of blood lipids( TG,LDL- C,TC,HDL- C),hemorheology and adverse reactions were recorded before and after treatment. Results Compared with before treatment,the clinical symptom score was significantly lower( P < 0. 05 or P < 0. 01); GLP- 1 increased at 60 min( P <0. 05),and there was no difference at other time points( P > 0. 05); the insulin and C- peptides had no significant change( P >0. 05); the glucose levels of blood glucose at 30,60,90,120 min were significantly decreased( P < 0. 05),and there were no hypoglycemia and other adverse reactions. Conclusion Tangmaikang can granule effectively improve the clinical symptoms of the newly diagnosed type 2 diabetic patients,improve insulin resistance and the efficiency of insulin,has no obvious promoting effect on GLP- 1. It is safe and deserves to be clinically promoted.更多还原